In a step towards advancing breast cancer treatment, researchers have pioneered a novel monoclonal antibody which specifically targets a certain type of breast cancer cell. This development offers a new tool to enhance the efficacy of treatment while also presenting an avenue for reducing the incidence and severity of side effects experienced by breast cancer patients. In the study, published in the open access International Journal of Molecular Sciences, researchers from Tohoku University devel